RxDoctor Payments Data

Erin Henderson

Nurse Practitioner · Olympia, WANPI 1578632527

Payments from drug & device makers

$4,679in general payments, 2019–2025

Across 123 payments — averaging $38.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Nevro Corp.$3K
  • Collegium Pharmaceutical, Inc.$614
  • Virtus Pharmaceuticals LLC$383
  • AbbVie$197
  • Medtronic$185
  • Globus Medical$144
  • plus $653 from 20 others

What the payments were for

  • Travel & lodging$77317%
  • Food & beverage$2,88062%
  • Education$1,02722%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,679 in reported general payments places this provider in the 95th percentile of 2,466 nurse practitioner providers in Washington.

See all nurse practitioner providers in Washington

Medicare billing

Part B allowed, 2024
$129,013
Medicare patients
277
Services billed
1,275

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Levorphanol Tartrate19$47,504
OxycontinOxycodone Hcl35$18,827
BelbucaBuprenorphine Hcl19$18,030
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen565$12,849
Xtampza ErOxycodone Myristate17$11,049
Oxycodone Hcl564$10,691
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen264$7,605
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl34$6,624
Buprenorphine Hcl139$5,778
Pregabalin254$5,329
Morphine Sulfate ErMorphine Sulfate227$4,268
Buprenorphine18$4,058
Naloxone Hcl51$3,617
Tramadol Hcl ErTramadol Hcl32$2,710
Lidocaine16$2,384

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Virtus Pharmaceuticals LLCLevorphanol Tartrate$383$47,50419 claims
Collegium Pharmaceutical, Inc.Belbuca, Xtampza Er$614$29,07836 claims
Hikma Pharmaceuticals USABuprenorphine-Naloxone, Buprenorphine Hcl, Buprenorphine, Morphine Sulfate$21$18,145258 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,466 nurse practitioner providers in Washington.

Other nurse practitioner in Olympia

See the full list for Washington

Where these figures come from

Is this you, or does something look wrong? →